Technical Analysis for DCPH - Deciphera Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Reversal New Lows Setup | Bearish Swing Setup | 3.31% | |
| 200 DMA Support | Bullish | 3.31% | |
| Outside Day | Range Expansion | 3.31% | |
| Gapped Down | Weakness | 3.31% | |
| Lower Bollinger Band Touch | Weakness | 3.31% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.21% | |
| NR7 | Range Contraction | 0.21% |
| Alert | Time |
|---|---|
| Up 1 ATR | about 5 hours ago |
| Possible Inside Day | about 7 hours ago |
| Rose Above 10 DMA | about 7 hours ago |
| 10 DMA Resistance | about 8 hours ago |
| Up 3% | about 8 hours ago |
Get a Trading Assistant
- Earnings date: 05/01/2024
Deciphera Pharmaceuticals, Inc. Description
Deciphera Pharmaceuticals, LLC is a United-States based clinical-stage biopharmaceutical company. The Company provides treatment for cancer patients. The Company focuses on developing tumor-targeted and immuno-targeted kinase inhibitors. Its switch control inhibitor platform is engaged in producing kinase inhibitors with distinct profiles and anti-cancer effects. Its tumor-targeting therapies include DCC-2618. DCC-2618 is a pan-KIT and PDGFR alpha kinase switch control inhibitor in clinical development for the treatment of KIT and/or Platelet-derived growth factor receptor alpha-driven cancers, including gastrointestinal stromal tumors, glioblastoma multiforme and systemic mastocytosis. Its Immuno-Targeted Therapies include DCC-3014 and Rebastinib. DCC-3014 is a potent and highly-selective immunokinase inhibitor targeting colony stimulating factor receptor 1 (CSF1R). Rebastinib is a TIE2 inhibitor targeting TIE2 expressing macrophages. Rebastinib is in the clinical development stage.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Immune System Drugs Clinical Development Cancer Treatment Gastrointestinal Antineoplastic Drugs Blastoma Glioblastoma Protein Kinase Inhibitor Tyrosine Kinase Receptors Targeted Therapy Glioblastoma Multiforme Platelet Mastocytosis Systemic Mastocytosis Gastrointestinal Stromal Tumor Gastrointestinal Stromal Tumors Treatment For Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 17.73 |
| 52 Week Low | 9.9 |
| Average Volume | 499,010 |
| 200-Day Moving Average | 14.07 |
| 50-Day Moving Average | 15.60 |
| 20-Day Moving Average | 14.98 |
| 10-Day Moving Average | 14.61 |
| Average True Range | 0.63 |
| RSI (14) | 45.05 |
| ADX | 17.29 |
| +DI | 12.56 |
| -DI | 23.03 |
| Chandelier Exit (Long, 3 ATRs) | 14.28 |
| Chandelier Exit (Short, 3 ATRs) | 15.89 |
| Upper Bollinger Bands | 15.87 |
| Lower Bollinger Band | 14.10 |
| Percent B (%b) | 0.31 |
| BandWidth | 11.82 |
| MACD Line | -0.29 |
| MACD Signal Line | -0.25 |
| MACD Histogram | -0.035 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 15.78 | ||||
| Resistance 3 (R3) | 15.71 | 15.28 | 15.59 | ||
| Resistance 2 (R2) | 15.28 | 14.99 | 15.31 | 15.52 | |
| Resistance 1 (R1) | 14.96 | 14.81 | 15.12 | 15.03 | 15.46 |
| Pivot Point | 14.53 | 14.53 | 14.61 | 14.56 | 14.53 |
| Support 1 (S1) | 14.21 | 14.24 | 14.37 | 14.28 | 13.84 |
| Support 2 (S2) | 13.78 | 14.06 | 13.81 | 13.78 | |
| Support 3 (S3) | 13.46 | 13.78 | 13.71 | ||
| Support 4 (S4) | 13.53 |
